HOME / CONTACT US
繁體版 / 简体版
 

MEDIA

Title Date
Announces the information about the 1st online investor's conference of 2023 2023-08-24
The Board of Directors resolved the amendments to the Company's "1st issue of the employee stock option certificate of 2023" 2023-08-11
The Board of Directors Approved the 2023 Q2 Consolidated Financial Statements 2023-08-11
SNS812, a broad-spectrum siRNA for COVID-19 infection, co-developed by Microbio (Shanghai) & Oneness has been agreed by US FDA to proceed with Phase 2 clinical trial. 2023-08-02
Announcement on behalf of major subsidiary Cotton Field Organic Co.,Ltd. the change of representative of juristic person director 2023-07-24
Announcement on behalf of major subsidiary Cotton Field Organic Co.,Ltd. the change of the general manager 2023-07-24
SNS812, a broad-spectrum siRNA co-developed by Microbio (Shanghai) and Oneness to treat SARS-CoV-2 infection,was greenlighted by TFDA to proceed with a Ph2 study. 2023-06-28
Submitted an IND to TFDA for a phase II clinical trial on a broad-spectrum antiviral siRNA developed jointly by Microbio (Shanghai) Co.,Ltd. and Oneness. 2023-06-09
Submitted an IND to US FDA for a phase II clinical trial on a broad-spectrum antiviral siRNA developed jointly by Microbio (Shanghai) Co.,Ltd. and Oneness. 2023-05-31
Announced BOD's resolution that the related matters of ex-rights and ex-dividend of year 2023. 2023-05-30
Announce major subsidiary Cotton Field Organic Co.,Ltd. of 2023 Shareholders' meeting to approve the release of non-compete restrictions for the director. 2023-05-19
Announcement on behalf of major subsidiary Cotton Field Organic Co.,Ltd. for shareholders' meeting resolution of the 2023 2023-05-19
The Company's 2023Q1 consolidated financial statements have been approved by the Board of Directors. 2023-05-11
Announce the Phase 1 clinical trial data of SNS812 a broad-spectrum antiviral siRNA for COVID-19 developed jointly by Microbio (Shanghai) Co.,Ltd. and Oneness. 2023-04-28
Approved the removal of restrictions imposed against the manager for involving in competing businesses by the BOD. 2023-04-20
To announce 2023 Shareholders' Meeting majoy resolutions. 2023-04-18
Approved the removal of restrictions imposed against the director for involving in competing businesses by the 2023 Shareholders' meeting. 2023-04-18
Announcement of dividends distribution approved by the BOD 2023-02-24
Announcement of the resolution of the BOD to issue new shares through capitalization of earnings and capital surplus 2023-02-24
Announcement of Year 2022 consolidated financial reports were approved by the BOD 2023-02-24